Ligand Pharma (LGND) Tops Q4 EPS by 49c

Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.36, $0.49 better than the analyst estimate of $0.87. Revenue for the quarter came in at $50.38 million versus the consensus estimate of $44.09 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• CoStar Group acquires Zonda for $800M, adding new home data
• BMO starts chip stocks coverage: Here are its preferred picks